Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University to Second Affiliated Hospital, Zhejiang University, School of Medicine
  2. Study description revised
    • Study title revised
    • Eligibility criteria shortened, about 5 words
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Assess the preliminary efficacy and safety of orelabrutinib in combination with the Pola-R-CHP regimen for the treatment of treatment-naive Non-GCB diffuse large B-cell lymphoma.
Trial Details
NCT Number NCT07078500
Lead Sponsor Second Affiliated Hospital, Zhejiang University, School of Medicine
Collaborators: The Second Affiliated Hospital of Jiaxing University, Taizhou First People's Hospital, Huzhou Central Hospital, Zhejiang Cancer Hospital, Dongyang People's Hospital, Yuyao People's Hospital, Taizhou Hospital, Shaoxing Central Hospital, Affiliated Hospital of Jiaxing University, Shaoxing People's Hospital, The Central Hospital of Lishui City, Second Affiliated Hospital of Wenzhou Medical University, Ningbo People's Hospital, The People's Hospital of Quzhou, Zhuji People's Hospital of Zhejiang Province, First People's Hospital of Hangzhou
Conditions
(from sponsor)		 Diffuse Large B-Cell Lymphoma (DLBCL)
Related terms Lymphoma, Large B-Cell, Diffuse
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov